Enhertu becomes top-selling new drug in India with Rs 58 crore in 2024 sales

AstraZeneca's Enhertu became the top-selling new drug in India in 2024, earning Rs 58 crore in its first year. This reflects the rising cancer cases in the country, with over 3,100 new drug brands launched, totaling Rs 1,097 crore in sales. The gastrointestinal segment saw the highest growth, generating Rs 167 crore, followed by oncology therapies at Rs 150 crore. India's pharmaceutical market surpassed Rs 2.2 lakh crore, growing at 8 percent, with GSK's Augmentin remaining the best-selling brand. Overall, the Indian pharmaceutical sector is expanding steadily, driven by new product launches and increasing healthcare demands, particularly in oncology and cardiac care.